Transforming growth factor-β3 protection of epithelial cells from cycle-selective chemotherapy in vitro

Biochemical Pharmacology

Volumn 53, Issue 8, 1997, Pages 1149-1159

  McCormack, E Siobhan ^a   Borzillo, Gary V ^a   Ambrosino, Claire ^a   Mak, Gilda ^a   Hamablet, Laurie ^a   Qu, Guo Ying ^a   Haley, John D ^a  

^a Oncogene Science Inc   (United States)

Author keywords

cell cycle, chemotherapy; chemoprotection; epithelial cells; TGF 3

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; PACLITAXEL; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA3; VINBLASTINE; VINCRISTINE;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL GROWTH; CELL PROTECTION; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG EFFECT; EPITHELIUM CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIUM; MINK; S PHASE; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030956840     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00094-4     Document Type: Article

References (60)

1. Booth C and Potten CS, Effects of IL-11 on the growth of intestinal epithelial cells in vitro. Cell Prolif 28: 581-594, 1995.
2. Potten CS, Interleukin-11 protects the clonogenic stem cells in murine small-intestinal crypts from impairment of their reproductive capacity by radiation. Int J Cancer 62: 356-361, 1995.
3. Moses HL, The biological actions of transforming growth factor β. In: Growth Factors from Genes to Clinical Application (Eds. Sara V, Hall K and Low H), pp. 141-155. Raven Press, New York, 1990.
4. Cox DA, Transforming growth factor-beta 3. Cell Biol Int 19: 357-371, 1995.
5. Alexandrow MG and Moses H, Transforming growth factor β and cell cycle regulation. Cancer Res 55: 1452-1457, 1995.
6. Kato J-Y, Matsushime H, Hiebert S, Ewen ME and Sherr CJ, Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7: 331-342, 1993.
7. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J-Y and Livingston DM, Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73: 487-497, 1993.
8. Ewen ME, Sluss HK, Whitehouse LL and Livingston DM, TGFβ inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell 74: 1009-1020, 1993.
9. 1 cyclins and cyclin-dependent protein kinases. Proc Natl Acad Sci USA 90: 10315-10319, 1993.
10. Hannon GJ and Beach D, p5Ink4b is a potential effector of cell cycle arrest mediated by TGF-β. Nature 371: 257-261, 1994.
11. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y and Wang X-F, Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92: 5545-5549, 1995.
12. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8: 9-22, 1994.
13. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM and Massague J, Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 62: 175-185, 1990.
14. Munger K, Pietenpol JA, Pittelkow MR, Holt JT and Moses HL, Transforming growth factor β1 regulation of c-myc expression, pRb phosphorylation, and cell cycle progression in keratinocytes. Cell Growth Differ 3: 291-298, 1992.
15. Strife A, Lambek C, Perez A, Darzynkiewicz Z, Skierski J, Gulati S, Haley JD, ten Dijke P, Iwata KK and Clarkson BD, The effects of transforming growth factor β3 on the growth of highly enriched hematopoietic cells derived from normal human bone marrow and peripheral blood. Cancer Res 51: 4828-4836, 1991.
16. Ruscetti FW, Dubois C, Falk LA, Jacobsen SE, Sing G, Longo DL, Wiltrout RH and Keller JR, In vivo and in vitro effects of TGF-β1 on normal and neoplastic haematopoiesis. In: Clinical Applications of TGF-β (Eds. Bock GR and Marsh J), pp. 212-227. John Wiley, Chichester, 1991.
17. Moses HL, Yang EY and Pietenpol JA, Regulation of epithelial proliferation by TGF-β. In: Clinical Applications of TGF-β (Eds. Bock GR and Marsh J), pp. 66-75. John Wiley, Chichester, 1991.
18. Potten CS, Owen G, Hewit D, Chadwick CA, Hendry H, Lord BI and Woolford LB, Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors. Gut 36: 864-873, 1995.
19. Sonis ST, Oral complications of cancer chemotherapy. In: Cancer. Principles and Practice of Oncology (Eds. DeVita VT Jr, Hellman S and Rosenberg SA), pp. 2385-2394. J. B. Lippincott Co., Philadelphia, 1993.
20. Pizzo PA, Meyers J, Freifeld AG and Walsh T, Infections in the cancer patient. In: Cancer. Principles and Practice of Oncology (Eds. DeVito VT Jr, Hellman S and Rosenberg SA), pp. 2292-2337. J. B. Lippincott Co., Philadelphia, 1993.
21. Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF and Sporn MA, Type β transforming growth factor. A bifunctional regulator of cell growth. Proc Natl Acad Sci USA 82: 119-123, 1985.
22. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M and Wilson JKV, Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338, 1995.
23. Weinberg RA, The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
24. Horowitz JM, Park S-H, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ, Minna JD, Dryja DP and Weinberg RA, Frequent inactivation of the retinoblastoma antioncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87: 2775-2779, 1990.
25. Hirama T and Koeffler HP, Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86: 841-854, 1995.
26. Howley PM, Role of the human papillomaviruses in human cancer. Cancer Res 51(Suppl): 5019-5022, 1991.
27. 1 regulation in human head and neck cancer. Cancer Res 55: 949-956, 1995.
28. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ and Look AT, Coamplification of the CDK4 gene with MDM2 and GL1 in human sarcomas. Cancer Res 53: 5535-5541, 1993.
29. Shipley GD, Pittlekow MR, Willie JJ Jr, Scott RE and Moses HL, Reversible inhibition of normal human prokeratinocyte proliferation by type β transforming growth factor-growth inhibitor in serum-free medium. Cancer Res 46: 2068-2071, 1986.
30. Masui T, Wakefield LM, Lechner JF, LaVeck MA, Sporn MB and Harris CC, Type β transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc Natl Acad Sci USA 83: 2438-2442, 1986.
31. Lemoli RM, Strife A, Clarkson BD, Haley JD and Gulati SC, TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro. Exp Hematol 20: 1252-1256, 1992.
32. 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J Exp Med 180: 1047-1057, 1994.
33. Pierce DE Jr and Coffey RJ, Therapeutic manipulation of cytokines: Transforming growth factor beta-1 protects mice treated with lethal doses of cytarabine. Am Surg 60: 18-25, 1994.
34. Sonis ST, Lindquist L, Van Vugt A, Stewart AA, Stam K, Qu G-Y, Iwata KK and Haley JD, Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor β3. Cancer Res 54: 1135-1138, 1994.
35. Mosmann T, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
36. Stewart AA, Haley JD, Qu G-Y, Stam K, Fenyo D, Chait BT, Marshak DR, Ng A-Y, Marley G and Iwata KK, Umbilical cord transforming growth factor-β3: Isolation, comparison with recombinant TGF-β3 and cellular localization. Growth Factors 13: 87-98, 1996.
37. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR, New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
38. Cooper MR and Cooper MR, Principles of medical oncology. In: American Cancer Society Textbook of Clinical Oncology (Eds. Holleb AI, Fink DJ and Murphy GP), pp. 47-68. American Cancer Society, Atlanta, 1991.
39. Chu E and Takimoto CH, Antimetabolites. In: Cancer. Principles and Practice of Oncology (Eds. DeVita VT Jr, Hellman S and Rosenberg SA), pp. 358-373. J. B. Lippincott Co., Philadelphia, 1993.
40. Schiff PB, Fant J and Horwitz SB, Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979.
41. Hartwell L, Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71: 543-546, 1992.
42. Murray AW, Creative blocks: Cell cycle checkpoints and feedback controls. Nature 359: 599-604, 1992.
43. Potten CS, Booth D and Haley JD, Pretreatment with transforming growth factor beta-3 protects small intestinal stem cells against radiation damage in vivo. Br J Cancer, in press.
44. Hawkins DS, Demers GR and Galloway DA, Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898, 1996.
45. 2 delay. Cancer Res 55: 1643-1648, 1995.
46. Taylor YC, Parsian AJ and Duncan PG, Differential post-irradiation caffeine response in normal diploid versus SV40-transformed human fibroblasts: Potential role of nuclear organization and protein-composition. Int J Radiat Biol 64: 57-70.
47. 1 checkpoint-competent cells. Cancer Res 55: 1639-1642, 1995.
48. Fan S, Smith ML, Rivet DJ II, Duba D, Zhan Q, Kohn KK, Fornance AJ and O'Connor PM, Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
49. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B, WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
50. Michalovitz D, Halevy O and Oren M, Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62: 671-680, 1990.
51. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD, Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935, 1992.
52. Koff A, Ohtsuki M, Polyak K, Roberts JM and Massagué J, Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-β. Science 260: 536-539, 1993.
53. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-720, 1996.
54. 1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
55. Thakkar NS and Potten CS, Inhibition of doxorubicin-induced apoptosis in vivo by 2-deoxy-D-glucose. Cancer Res 53: 2057-2060, 1993.
56. Amento EP and Beck LS, TGF-β and wound healing. In: Clinical Applications of TGF-β (Eds. Bock GR and Marsh J), pp. 115-129. John Wiley, Chichester, 1991.
57. Roberts AB, Sporn MB and Assoian RK, Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83: 4167-4171, 1986.
58. Merwin JR, Roberts A, Kondaiah P, Tucker A and Madri J, Vascular cell responses to TGF-β3 mimic those of TGF-β1 in vitro. Growth Factors 5: 149-158, 1991.
59. Postlethwaite AE, Keski-Oja J, Moses HL and Kang AH, Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor β. J Exp Med 165: 251-256, 1987.
60. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB and Sporn MB, Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 84: 5788-5792, 1987.